Prefillable syringe compatible pharma-grade active pharmaceutical ingredient (API) for tablet, capsule, granule, oral, and injectable formulation is supplied as a multi-compendial material produced under current good manufacturing practice. The material is specified for residual solvents per ICH Q3C, elemental impurities per ICH Q3D, microbial enumeration per USP <61>, specified microorganisms per USP <62>, and bacterial endotoxins per USP <85>. The API is intended for direct compression and wet granulation tableting, hard-shell capsule filling, granule and oral suspension manufacture, oral solution compounding, and sterile injectable solution or suspension filling into prefilled syringes. The product scope includes staked-needle and needle-free syringe formats, with barrel dimensions selected from 1 mL long, 2.25 mL, 5 mL, and 10 mL nominal volumes where the container system conforms to ISO 11040-4:2015 for glass or ISO 11040-6:2012 for plastic.

Container closure model selection is assigned at the syringe system level rather than as a single catalogue number. Glass barrels are Type I borosilicate, and plastic barrels are typically cyclic olefin polymer or polypropylene. Plunger stoppers are chlorobutyl or bromobutyl elastomer, either uncoated or fluoropolymer-laminated, and are qualified against USP <381> and Ph. Eur. 3.2.9. Staked needles, where present, are low-tungsten designs to limit tungsten extractables that can appear as subvisible particles after filling and storage. The tip closure is either an elastomeric tip cap or a rigid cap with elastomeric liner, selected to maintain sterility and container closure integrity under transportation and low-temperature storage.

For tablet and capsule manufacture, the API is processed by direct compression or high-shear wet granulation. On production-scale rotary tablet presses, the blend is characterized before compression using particle size distribution by laser diffraction per USP <429>, bulk and tapped density per USP <616>, and flow through an orifice per USP <1174>. Compaction behavior is evaluated with an instrumented press or compaction simulator to detect capping and lamination risks. Capsule filling on intermittent-motion dosator or tamping-pin machines requires control of powder bed height and stratified blend sampling. Granulation endpoint is controlled by loss on drying per USP <731> and Karl Fischer titration per USP <921>; the dried granule is milled and sieved using USP <786> analytical sieving.

Blend uniformity is assessed according to USP <905> and dissolution according to USP <711> with apparatus selected for the dosage form. Because oral solid dosage forms do not require depyrogenation or sterility, oral-grade material may be produced on multiproduct equipment with cleaning validation appropriate to the lower microbiological risk. The injectable grade, by contrast, is manufactured in dedicated equipment or in validated multiproduct campaigns with cleaning verification per ICH Q7 and 21 CFR 211.67.

For granule and oral suspension manufacture, the API is wet-massed with a binder solution in a high-shear mixer or fluid-bed granulator. Spray rate, inlet air temperature, and atomization pressure are adjusted to prevent overwetting and API migration. The dried granule is milled and sieved; residual moisture is controlled by loss on drying per USP <731> and Karl Fischer titration per USP <921>. Sachet fill weights are verified with in-process checkweighers, and final blend uniformity is assessed by stratified sampling. Published data for this specific configuration is limited.

For oral solutions, the API is dissolved in a suitable solvent system, and pH is adjusted to maintain solubility and stability. Preservative effectiveness is tested per USP <51> where applicable. Homogeneity is verified by sampling from top, middle, and bottom of the mixing vessel. The oral liquid process does not require sterility, but bioburden is controlled to acceptance criteria based on the intended route.

What Is the Difference Between an Oral-Grade API and a Prefillable-Syringe-Compatible Injectable Grade?

The injectable grade is differentiated by low bioburden, absence of specified microorganisms, controlled endotoxin content, particulate matter limits per USP <788> or USP <787> as applicable, and elemental impurity limits calculated by ICH Q3D Option 1. Residual solvents are limited per ICH Q3C, with Class 1 solvents controlled at the following concentrations: benzene 2 ppm, carbon tetrachloride 4 ppm, 1,2-dichloroethane 5 ppm, 1,1-dichloroethene 8 ppm, and 1,1,1-trichloroethane 1500 ppm. An oral-grade API may not carry endotoxin, particulate, or sterility specifications because the final dosage form is not presented as a parenteral. Substitution of oral-grade material into an injectable process would violate 21 CFR 211.84 because the material would not have been tested against the quality attributes appropriate for its intended use.

Compared with uncoated elastomer plunger stoppers, fluoropolymer-laminated stoppers reduce leachable zinc and sulfur species and often lower visible particle counts in stability studies. However, the laminate can shift break-loose and glide force profiles. Mechanical testing is therefore performed on the finished syringe according to ISO 11040-8:2016. Break-loose force and glide force are measured using a constant-rate tensile/compression tester with a load cell appropriate to the expected force range; acceptance criteria are product-specific and are established during design verification. Published data for this specific configuration is limited, so universal numeric values are not applicable.

Extractable and Leachable Risk Management in Silicone-Oiled Prefillable Syringe Systems

Prefilled syringe systems introduce contact materials that are not present in glass vials: silicone oil, elastomer stoppers, tip cap rubbers, tungsten residues from needle insertion, and potential adhesive or ink components. Extractables screening is conducted per USP <1663> using extraction solvents matched to the formulation polarity and exaggerated temperatures, such as 40 °C for 30 days or 50 °C for 7 days. Leachables testing is then performed per USP <1664> on stability samples. The analytical evaluation threshold is derived from the safety concern threshold or permitted daily exposure; published data for this specific configuration is limited, so the threshold is calculated case-by-case.

Silicone oil can be detected as subvisible droplets by flow imaging, and tungsten residues can appear as discrete particles if low-tungsten needles are not used. On high-speed filling lines, silicone oil redistribution after autoclaving can produce visible droplet rings at the barrel shoulder; this is controlled by validated silicone oil application and curing before filling. Fluoropolymer-laminated stoppers reduce extractables compared with uncoated elastomers, but may require different insertion vacuum settings to avoid bubble formation or stopper deformation. Stopper insertion speed and vacuum level are adjusted during engineering runs to keep residual bubble size below the reject limit established for the product.

For injectable solution preparation, the API is dissolved in Water for Injection, pH adjusted, and filtered through a 0.22 µm rated membrane. Filter integrity is tested before and after filling with a bubble point or diffusive flow method per ASTM F838-20 or equivalent. The solution is filled aseptically on a rotary piston or peristaltic pump line inside a restricted access barrier system or isolator. Fill volume is verified by in-process checkweighing, and visible particles are controlled according to USP <790>. Subvisible particulate matter is measured per USP <788>; for containers not greater than 100 mL, the light obscuration limits are not more than 6000 particles per container at ≥10 µm and not more than 600 particles per container at ≥25 µm.

Terminal sterilization of a prefilled syringe is considered only when the API demonstrates degradation below the specification threshold under moist heat at 121 °C for 15 min. Silicone oil redistribution and plunger stopper compression set are evaluated after autoclaving. For heat-sensitive formulations, aseptic filtration and filling are required. Container closure integrity is tested per USP <1207> using deterministic methods such as vacuum decay or helium leak. The test must demonstrate no breach of the sealed syringe across the intended shelf life, including after thermal cycling and drop testing.

On an aseptic filling line, batch-to-batch variance in stopper coating thickness can produce a bimodal distribution of break-loose force. Production-scale failure modes include syringe tip cap pop-off during vacuum leak testing, needle shield misalignment, and silicone oil droplet accumulation at the barrel shoulder after terminal sterilization. These are addressed with incoming component dimensional inspection per ISO 11040-4:2015 and ISO 11040-5:2012, and with periodic force testing on a tensile/compression tester. In-process rejection of visible particles is recorded by automated inspection; recurrent rejection spikes require investigation of stopper lot, needle lot, and silicone oil application conditions.

The API is released by HPLC assay under a validated method per ICH Q2(R1), with system suitability requirements for resolution, tailing, and replicate injection precision. Impurities are controlled at reporting, identification, and qualification thresholds per ICH Q3A. Enantiomeric or polymorphic form is controlled where relevant by X-ray powder diffraction or chiral HPLC. Residual solvents are determined by headspace gas chromatography. Elemental impurities are determined by inductively coupled plasma mass spectrometry per ICH Q3D.

Stability studies for the prefillable syringe product are conducted under ICH Q1A(R2) conditions: 25 °C/60% RH for room temperature storage, 40 °C/75% RH for accelerated, and 5 °C or -20 °C for refrigerated or frozen products. Test intervals include initial, 3, 6, 9, and 12 months, followed by annual intervals. The syringe may be stored tip-up or tip-down to detect orientation-dependent leachables or silicone oil migration. Published data for this specific configuration is limited.

Relative to a standard vial-and-stopper presentation, the prefilled syringe format eliminates a transfer step at point of administration and reduces dose measurement variability, but it adds contact with silicone oil and a narrower container closure geometry. Compared with oral tablet or capsule grades, the injectable grade requires depyrogenation, particulate and endotoxin controls, and more extensive stability testing under ICH Q1A(R2) and ICH Q5C as applicable. Compared with a syringe supplied empty for clinical use, the prefilled system is regulated as a drug-device combination product in some jurisdictions and must address extractables, leachables, and device functional performance. The material is not interchangeable with technical-grade or oral-grade API unless the container closure and route-specific quality attributes are met.